By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678


October 1991


Founders: Martin Gleave and Scott Daniel Cormack

CEO and Founder: Scott Cormack

CMO (Medical): Cindy Jacobs

CFO: John Bencich


Please click here for.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: OncoGenex
Symbol: OGXI

Company News
Achieve Life Science Announces Closing Of Merger With OncoGenex (OGXI) 8/2/2017 11:33:54 AM
Achieve Life Science And OncoGenex (OGXI) Announce Form S-4 Registration Statement Declared Effective By SEC 6/14/2017 7:28:16 AM
OncoGenex (OGXI) Reports Financial Results For First Quarter 2017 5/15/2017 10:24:08 AM
OncoGenex (OGXI) To Report First Quarter 2017 Financial Results On May 15, 2017 5/9/2017 11:38:16 AM
Achieve Life Science And OncoGenex (OGXI) Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT") 3/8/2017 10:48:48 AM
Achieve Life Science And OncoGenex (OGXI) Announce Strategic Collaboration With The OncoGenex (OGXI) To Advance The Development Of Cytisine For Smoking Cessation 3/1/2017 7:23:02 AM
OncoGenex (OGXI) Reports Financial Results For Year End 2016 2/23/2017 12:17:04 PM
OncoGenex (OGXI) Reports Financial Results For Year End 2016 2/23/2017 10:22:05 AM
OncoGenex (OGXI) Release: Data Support Continued Exploration Of Hsp27 Inhibition In Bladder And Prostate Cancers 2/21/2017 9:41:27 AM
OncoGenex (OGXI) Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex (OGXI) 2017 Genitourinary Cancers Symposium 2/21/2017 7:28:58 AM